Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) was a big mover last session with its shares rising over 19% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent downtrend of the company as the stock has lost nearly 2% since April 24. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) weekly performance is 23.42%. On last trading day company shares ended up $0.975. Analysts mean target price for the company is $2.83. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) distance from 50-day simple moving average (SMA50) is -10.35%.
Mizuho believes Clovis Oncology Inc (NASDAQ:CLVS) ‘ early data for CO-1686 is encouraging compared to AstraZeneca’s (AZN) AZD9291. The firm has some concerns around the safety profile for AZD9291. Mizuho says results from Clovis’ key ASCO abstract confirmed promising initial data for CO-1686 in NSCLC. Clovis Oncology Inc (NASDAQ:CLVS) shares fell -5.55% in last trading session and ended the day on $55.96. CLVS return on assets is -22.30%. Clovis Oncology Inc (NASDAQ:CLVS) quarterly performance is -17.26%.
Enzymotec Ltd (NASDAQ:ENZY), reports that it was informed that AarhusKarlshamn AB, or AAK, a Sweden-based, global producer of specialty oils that is Enzymotec’s joint venture partner in Advanced Lipids AB, submitted a claim for arbitration against the Company seeking certain declaratory relief with respect to the joint venture agreement. Enzymotec Ltd (NASDAQ:ENZY) weekly performance is -33.47%. On last trading day company shares ended up $12.90. Analysts mean target price for the company is $29.00. Enzymotec Ltd (NASDAQ:ENZY) distance from 50-day simple moving average (SMA50) is -40.85%.
DARA Biosciences Inc (NASDAQ:DARA)announced its support for Neuropathy Awareness Week which is being observed during the week of May 12, 2014 and sponsored in the U.S. by The Neuropathy Association. DARA Biosciences Inc (NASDAQ:DARA) shares moved down -7.08% in last trading session and was closed at $1.05, while trading in range of $1.04 – $1.16. DARA Biosciences Inc (NASDAQ:DARA) year to date (YTD) performance is -61.11%.
On May 12, 2014, Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) reported its financial results and corporate update for the first quarter ended March 31, 2014. For the first quarter of 2014, Ultragenyx reported a net loss attributable to common stockholders of $18.4 million, or $0.85 per share, basic and diluted, compared with a net loss attributable to common stockholders for the first quarter of 2013 of $8.2 million, or $2.84 per share, basic and diluted. Net loss attributable to common stockholders differs from net loss due to dividends and other charges related to outstanding preferred stock, which was converted into common stock upon the company’s initial public offering. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) ended the last trading day at $34.48. Company weekly volatility is calculated as 8.06% and price to cash ratio as 19.40. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) showed a negative weekly performance of -5.66%.
Leave a Reply